Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications
FDA Approval Summary: Teclistamab-A Bispecific CD3 T-Cell Engager for Patients with Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 18, 2024
Trends in the approval of cancer therapies by the FDA in the twenty-first century.
Journal: Nature reviews. Drug discovery
Published: May 10, 2023
Minimal Residual Disease Data in Hematologic Malignancy Drug Applications and Labeling: An FDA Perspective.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 18, 2022
FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 24, 2022
Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials.
Journal: Blood advances
Published: June 08, 2021
Perspectives on Drug Development in Multiple Myeloma-Looking Forward to 2025.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: March 25, 2021
Germline mutations in the alternative pathway of complement predispose to HELLP syndrome.
Journal: JCI insight
Published: December 08, 2017
A hypomorphic PIGA gene mutation causes severe defects in neuron development and susceptibility to complement-mediated toxicity in a human iPSC model.
Journal: PloS one
Published: December 08, 2016
Last Updated: 09/26/2026